The reason why changes in parathyroid hormone or FGF23 do not relate to changes in NT-proBNP may be due to the short intervention period or because these factors are only biomarkers of other mechanisms involved in the pathophysiology of left ventricular hypertrophy and heart failure in patients with CKD. Here, NPPB is linked to heart failure.